コーパス検索結果 (right1)
通し番号をクリックするとPubMedの該当ページを表示します
1 similarly, but they identified different areas as important as compared with patients.
4 e, significantly more group B patients were in sinus rhythm as compared with patients in group A (30 [57%] versus 18 [34%
5 significantly more common among patients in the 2003 cohort as compared with patients in the 1998 trial (adjusted odds ra
6 e frequently in patients in the lower tertile (Mg <2 mg/dL) as compared with patients in the higher tertile (Mg >2.3 mg/d
7 disease of 3.12 (P<0.001) and 3.64 (P<0.001), respectively, as compared with patients in the lowest quartile.
9 ienced a significantly lower risk of subsequent HF or death as compared with patients in whom 1-year BNP levels were high
11 onths), significantly more group B patients were free of AF as compared with patients of group A (49 [92%] versus 39 [74%
12 cians with adenoma detection rates in the highest quintile, as compared with patients of physicians with detection rates
13 capecitabine group died of treatment-related complications; as compared with patients receiving capecitabine, twice as ma
15 nd 0.49 (P = 0.02), respectively, in patients receiving MTX as compared with patients receiving placebo.
19 open procedure were more likely to develop a complication, as compared with patients undergoing an laparoscopic procedur
20 o describe the new onset of 1 or more dysphotopsia symptoms as compared with patients undergoing nasal/temporal LPI (8.4%
21 lled prognostic disclosure offered more realistic estimates as compared with patients who did not (median, 12 months; int
24 cognitively improved (median aortic valve area 0.60 cm(2)) as compared with patients who did not improve (median aortic
25 incompatible live donors had a substantial survival benefit as compared with patients who did not undergo transplantation
27 Multivariable-adjusted hazard ratios for statin users, as compared with patients who had never used statins, were 0.
28 10.0+/-1.3; P=0.004 and 19.4+/-2.7 vs. 9.0+/-1.7; P=0.002), as compared with patients who had no rejection.
29 positive for IgM aCL at weeks 30 and 54 (4.8% [10 of 208]) as compared with patients who received placebo plus MTX (1.1%
31 g-term survival advantage among patients who underwent CABG as compared with patients who underwent PCI.
32 duration of >or=24 months showed a greater rate of decline as compared with patients with a disease duration of <24 mont
34 lesions and had decreased vascular proliferation on biopsy as compared with patients with antiphospholipid antibodies wh
36 ure in the management of patients with pain related to CPPD as compared with patients with chronic pancreatitis secondary
37 r 2 was also observed in patients with non-Lofgren syndrome as compared with patients with Lofgren syndrome.
39 ntation had the lowest 5-year rate of graft survival (54%), as compared with patients with non-complement-binding donor-s
40 ith excess sodium intake had no decrease in time to relapse as compared with patients with non-excess sodium intake.
41 th extended oligoarthritis, the more severe subtype of JIA, as compared with patients with persistent oligoarthritis, the
42 are immunologically closer to relapsing-remitting patients as compared with patients with primary-progressive MS.
43 CD8+ polyfunctional T cells expressing multiple cytokines, as compared with patients with prolonged episodes of BK virem
44 specimens from patients with non-alcoholic steatohepatitis as compared with patients with simple steatosis or controls.
46 tcome of patients with ACS undergoing coronary angiography, as compared with patients with stable coronary artery disease
48 essed increased frequencies of EBV-specific CD8(+) T cells, as compared with patients with undetectable EBV loads.
49 These patients have better response to bortezomib as compared with patients within other clusters (70% versus 2
50 CS was lowest in this group (19 283 US$ versus 464 399 US$) as compared with patients without CAC.
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。